off-label use of glp-1 agonists for obesity in 2016 Weight Reduction with and Paths Discontinuation While Maintaining Weight Loss GLP1 Receptor Agonists—Effects beyond Obesity

Unlike Mounjaro, however, Zepbound is FDA-approved to support weight management for people living with obesity or overweight who have at least one weight-related condition, such as type 2 diabetes, high cholesterol, or hypertension (high blood pressure)

Nauck et al., 2021a)

o OPKO Health, Inc

Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial

The starting dose of retatrutide and optimal dose selection will likely be refined further when FDA labeling is finalized

Key takeaways include: Obesity drug coverage in Medicaid remains limited, with 13 state Medicaid programs covering GLP-1s for obesity treatment under fee-for-service (FFS) as of January 2026